CSF3 and cancer: Pegfilgrastim (Neulasta®, Amgen Inc., Thousand Oaks, CA, USA) is a pegylated recombinant human G-CSF that is indicated to decrease the incidence of infection, as manifested by FN, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs [12, 13].